



Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Duft *et al.*

Appln. No.: 08/870,762

Filed: June 6, 1997

For: METHODS FOR TREATING
OBESITY

Art Unit: 1645

Examiner: Devi, S..

Atty. Docket: 030639.0044.CPA2

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
APR 20 2005
TECH CENTER 1600/2900

TRANSMITTAL

Dear Sir:


Enclosed herewith for filing in the above-identified application is the following document:

- Revocation of Prior Power of Attorney, Appointment of New Attorneys of Record
and Change of Correspondence Address with copy of Assignment document.

The Commissioner is authorized to charge any fees associated with the present submission to Deposit Account No. 010535.

Respectfully Submitted,

AMYLIN PHARMACEUTICALS, INC.

By: 
Molly A. Holman, Ph.D.
Reg. No. 40,022

AMYLIN PHARMACEUTICALS, INC.
9373 Towne Centre Drive
San Diego, California 92121
Telephone: (858) 552-2200
Facsimile: (858) 552-1936

CERTIFICATE OF TRANSMISSION
(37 C.F.R. §1.8)

I hereby certify that this paper is being transmitted to the United States Patent and Trademark Office on the date shown below via facsimile.

Date of Deposit 2/26/03

DianeTrus
Name of Person Faxing Paper
DianeTrus
Signature of Person Faxing Paper



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Duft et al.

Appln. No.: 08/870,762

Filed: June 6, 1997

For: METHODS FOR TREATING
OBESITY

Art Unit: 1645

Examiner: Devi, S.

Atty. Docket: 030639.0044.CPA2

Confirm. No.: 7328

RECEIVED
APR 20 2005
TECH CENTER 1600/2900

**Revocation of Prior Power of Attorney,
Appointment of New Attorneys of Record and
Change of Correspondence Address**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Amylin Pharmaceuticals, Inc. is the assignee of the entire right, title and interest in the above-identified application by virtue of the assignment attached hereto. The undersigned, having express authority to represent Amylin Pharmaceuticals, Inc. as assignee, hereby revokes all powers of attorney heretofore given in the above-captioned application and appoints the attorneys and agents listed below with full power of substitution, association, and revocation, to prosecute said application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

Matthew N. Bathon, Reg. No. 51,441
Timothy C. Bickham, Reg. No. 41,618
Scott A. Chambers, Reg. No. 37,573
Jay Chawla, Reg. No. 44,073
June E. Cohan, Reg. No. 43,741
Danielle M. Edwards, Reg. No. 51,645
James R. Farrand, Reg. No. 38,136
Joel M. Freed, Reg. No. 25,101
Dawn M. Gardner, Reg. No. 44,118
Barry Herman, Reg. No. 51,254
Leslie M. Hill, Reg. No. 51,805
Leslie L. Jacobs, Jr., Reg. No. 40,659
David R. Marsh, Reg. No. 41,408

Molly A. Holman, Reg. No. 40,022

Joseph Micallef, Reg. No. 39,772
Lisa A. Penoyer, Reg. No. 51,204
Holly Logue Prutz, Reg. No. 47,755
Joseph W. Ricigliano, Reg. No. 48,511
Sidney A. Rosenzweig, Reg. No. 43,893
William Sekyi, Reg. No. 45,831
Ali R. Sharifahmadian, Reg. No. 48,202
Michael J. Songer, Reg. No. 39,841
Marcia Sundeen, Reg. No. 30,893
Milan M. Vinnola, Reg. No. 45,979
Todd A. Wagner, Reg. No. 35,399
Robert Jones Worrall, Reg. No. 37,969
Paul Zegger, Reg. No. 33,821,

all of Arnold & Porter, and

Joanna L. Moore, Reg. No. 44,950,

both of Amylin Pharmaceuticals, Inc.

Please address future correspondence to

ARNOLD & PORTER
Attn: IP Docketing Department, Room 1126B
555 Twelfth Street, NW
Washington, DC 20004-1206

Telephone calls should be directed to Milan M. Vinnola, (202) 942-5000 and facsimile transmissions to (202) 942-5999.

FOR: Amylin Pharmaceuticals, Inc.

SIGNATURE: 

BY: Lloyd A. Rowland

TITLE: Vice President and General Counsel

DATE: 2/21/03

CALIFORNIA

ALL-PURPOSE

ACKNOWLEDGEMENT

STATE OF CALIFORNIA)

COUNTY OF San Diego)

On 01/22/98 before me. Kara Lee Swedberg, Notary Public.
DATE NAME, TITLE OF OFFICER - E.G., "JANE D.", NOTARY PUBLIC

personally appeared. Bradford J. Duff
personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are
subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized
capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the
person(s) acted, executed the instrument.

WITNESS my hand and official seal.



Kara Lee Swedberg (SEAL)
NOTARY PUBLIC SIGNATURE

OPTIONAL INFORMATION

TITLE OR TYPE OF DOCUMENT Assignment

DATE OF DOCUMENT January 22, 1998 NUMBER OF PAGES One

SIGNER(S) OTHER THAN NAMED ABOVE Orville G. Kolterman

CALIFORNIA

ALL-PURPOSE

ACKNOWLEDGEMENT

STATE OF CALIFORNIA

COUNTY OF San Diego

On 01/26/98 before me, Kara Lee Swedberg Notary Public
DATE NAME, TITLE OF OFFICER - E.G., "JANE DOE, NOTARY PUBLIC"

personally appeared, Orville G. Kolterman

personally known to me (or proved to me on the basis of satisfactory evidence) to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

WITNESS my hand and official seal.



NOTARY PUBLIC SIGNATURE

OPTIONAL INFORMATION

TITLE OR TYPE OF DOCUMENT Assignment

DATE OF DOCUMENT January 26, 1998 NUMBER OF PAGES One

SIGNER(S) OTHER THAN NAMED ABOVE Bradford J. Duft

ASSIGNMENT

WHEREAS, we, Bradford J. Duft, a citizen of the United States of America, residing at 5762 Loma Verde, Rancho Santa Fe, California 92067, and Orville G. Kolterman, a citizen of the United States of America, residing at 15793 Hidden Valley Drive, Poway, California 92064, have invented new and useful Methods for Treating Obesity, for which an application for United States Letters Patent was filed on June 6, 1997, and assigned Serial No. 08/870,762; and

WHEREAS, Amylin Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware, and having its principal place of business at 9373 Towne Centre Drive, San Diego, California 92121, is desirous of acquiring the exclusive right, title and interest in and to said invention and to the Letters Patent to be granted and issued therefor in the United States of America and its territories and possessions, and all countries foreign thereto;

NOW, THEREFORE, for a valuable consideration, the receipt of which is hereby acknowledged, we, the said Bradford J. Duft and Orville G. Kolterman, do hereby sell, assign, transfer and set over unto the said Amylin Pharmaceuticals, Inc., its successors and assigns, the full and exclusive right, title and interest in and to the said invention, and in and to any and all Letters Patent to be granted and issued therefor, not only for, to and in the United States of America, its territories and possessions, but for, to and in all other countries, including all priority rights under the International Convention; and we hereby authorize and request the Commissioner of Patents and Trademarks to issue said Letters Patent to said Amylin Pharmaceuticals, Inc., its successors and assigns, in accordance with this Assignment.

WITNESS my hand at San Diego, California this 22nd day of January, 1998




Bradford J. Duft

COUNTY OF SAN DIEGO)
STATE OF CALIFORNIA) ss.

On this ____ day of _____, 1997 before me a Notary Public, personally appeared Bradford J. Duft, proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to this instrument, and acknowledged that he executed it.

Notary Public in and for
said County and State

WITNESS my hand at San Diego, California this 26th day of January, 1998



Orville G. Kolterman

COUNTY OF SAN DIEGO)
STATE OF CALIFORNIA) ss.

On this ____ day of _____, 1997 before me a Notary Public, personally appeared Orville G. Kolterman, proved to me on the basis of satisfactory evidence to be the person whose name is subscribed to this instrument, and acknowledged that he executed it.

Notary Public in and for
said County and State

TO:Auto-reply fax to 858-552-2212 COMPANY:

Auto-Reply Facsimile Transmission



TO: Fax Sender at 858-552-2212

Fax Information

Date Received:

Total Pages:

2/26/03 9:08:50 PM [Eastern Standard Time]

7 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
Cover
Page
=====>

Amylin 858-552-2212	Feb 26, 2003 06:08PM PST >USPTO	Pg 1 of 7
 <p>AMYLIN PHARMACEUTICALS</p> <p>9373 Towne Centre Drive Suite 250 San Diego, CA 92121 (858)-552-2200 (858)-552-1936</p> <hr/> <p style="text-align: center;">FACSIMILE TRANSMISSION</p> <p>DATE: 2/26/03</p> <p>TO: Devi, S. Art Unit 1645</p> <p>COMPANY: United States Patent Office</p> <p>FAX NO.: 703-672-6306</p> <p>FROM: Amylin Pharmaceuticals, Inc.</p> <p>RE: U.S. Serial No. 08/870,762 Attorney Docket No. 030639.0044.CPA2</p> <p>Number of pages being transmitted (including this cover sheet): 7</p> <hr/> <p>ATTACHMENT:</p> <ul style="list-style-type: none"> - Transmittal; - Revocation of Prior Power of Attorney, Appointment of New Attorneys of Record and Change of Correspondence Address, with copy of Assignment Document. <p><i>This facsimile and the information it contains are intended to be a confidential communication only to the person or entity to whom it is addressed. If you have received this facsimile in error, please notify us by telephone and return the original fax to this office by mail.</i></p>		

**RECEIVED
DOCKET DEPT.
ARNOLD & PORTER**

MAR 10 2003

WASHINGTON, D.C.